A BILL 
To rescue domestic medical manufacturing activity by pro-
viding incentives in economically distressed areas of the 
United States and its possessions. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Medical Manufac-
4
turing, Economic Development, and Sustainability Act of 
5
2020’’ or the ‘‘MMEDS Act of 2020’’. 
6
19:02 Jul 28, 2020
H7527
2 
•HR 7527 IH
SEC. 2. ECONOMICALLY DISTRESSED ZONES. 
1
(a) IN GENERAL.—Chapter 1 of the Internal Rev-
2
enue Code of 1986 is amended by adding at the end the 
3
following new subchapter: 
4
‘‘Subchapter AA—Medical Manufacturing in 
5
Economically Distressed Zones 
6
‘‘SUBCHAPTER AA—MEDICAL MANUFACTURING IN ECONOMICALLY DISTRESSED 
ZONES 
‘‘Sec. 1400AA–1. Medical manufacturing in economically distressed zone credit. 
‘‘Sec. 1400AA–2. Credit for economically distressed zone products and services 
acquired by domestic medical manufacturers. 
‘‘Sec. 1400AA–3. Special rules to secure the national supply chain and for the 
production of population health products. 
‘‘Sec. 1400AA–4. Designation of economically distressed zones. 
‘‘SEC. 1400AA–1. MEDICAL MANUFACTURING IN ECONOMI-
7
CALLY DISTRESSED ZONE CREDIT. 
8
‘‘(a) ALLOWANCE OF CREDIT.—There shall be al-
9
lowed as a credit against the tax imposed by subtitle A 
10
for the taxable year an amount equal 40 percent of the 
11
sum of— 
12
‘‘(1) the aggregate amount of the taxpayer’s 
13
medical manufacturing economically distressed zone 
14
wages for such taxable year, 
15
‘‘(2) the allocable employee fringe benefit ex-
16
penses of the taxpayer for such taxable year, and 
17
‘‘(3) the depreciation and amortization allow-
18
ances of the taxpayer for the taxable year with re-
19
spect to qualified medical manufacturing facility 
20
property. 
21
19:02 Jul 28, 2020
H7527
3 
•HR 7527 IH
‘‘(b) DENIAL OF DOUBLE BENEFIT.—Any wages or 
1
other expenses taken into account in determining the cred-
2
it under this section may not be taken into account in de-
3
termining the credit under sections 41, and any other pro-
4
vision determined by the Secretary to be substantially 
5
similar. 
6
‘‘(c) DEFINITIONS AND SPECIAL RULES.—For pur-
7
poses of this section— 
8
‘‘(1) 
ECONOMICALLY
DISTRESSED
ZONE 
9
WAGES.— 
10
‘‘(A) IN
GENERAL.—The term ‘economi-
11
cally distressed zone wages’ means amounts 
12
paid or incurred for wages of an employee by 
13
the taxpayer for the taxable year which are— 
14
‘‘(i) in connection with the active con-
15
duct of a trade or business of the taxpayer, 
16
and 
17
‘‘(ii) the principal place of employ-
18
ment of whom is in a qualified medical 
19
manufacturing facility of such taxpayer. 
20
‘‘(B) LIMITATION ON AMOUNT OF WAGES 
21
TAKEN INTO ACCOUNT.— 
22
‘‘(i) IN
GENERAL.—The amount of 
23
wages which may be taken into account 
24
under subparagraph (A) with respect to 
25
19:02 Jul 28, 2020
H7527
4 
•HR 7527 IH
any employee for any taxable year shall 
1
not exceed the contribution and benefit 
2
base determined under section 230 of the 
3
Social Security Act for the calendar year 
4
in which such taxable year begins. 
5
‘‘(ii) TREATMENT OF PART-TIME EM-
6
PLOYEES, ETC.—If— 
7
‘‘(I) any employee is not em-
8
ployed by the taxpayer on a substan-
9
tially full-time basis at all times dur-
10
ing the taxable year, or 
11
‘‘(II) the principal place of em-
12
ployment of any employee is not with-
13
in an economically distressed zone at 
14
all times during the taxable year, 
15
the limitation applicable under clause (i) 
16
with respect to such employee shall be the 
17
appropriate portion (as determined by the 
18
Secretary) of the limitation which would 
19
otherwise be in effect under clause (i). 
20
‘‘(C) TREATMENT
OF
CERTAIN
EMPLOY-
21
EES.—The term ‘economically distressed zone 
22
wages’ shall not include any wages paid to em-
23
ployees who are assigned by the employer to 
24
perform services for another person, unless the 
25
19:02 Jul 28, 2020
H7527
5 
•HR 7527 IH
principal trade or business of the employer is to 
1
make employees available for temporary periods 
2
to other persons in return for compensation. 
3
‘‘(2) ALLOCABLE EMPLOYEE FRINGE BENEFIT 
4
EXPENSES.— 
5
‘‘(A) IN
GENERAL.—The term ‘allocable 
6
employee fringe benefit expenses’ means the ag-
7
gregate amount allowable as a deduction under 
8
this chapter to the taxpayer for the taxable year 
9
for the following amounts which are allocable to 
10
employment in a qualified medical manufac-
11
turing facility: 
12
‘‘(i) Employer contributions under a 
13
stock bonus, pension, profit-sharing, or an-
14
nuity plan. 
15
‘‘(ii) 
Employer-provided 
coverage 
16
under any accident or health plan for em-
17
ployees. 
18
‘‘(iii) The cost of life or disability in-
19
surance provided to employees. 
20
‘‘(B) ALLOCATION.—For purposes of sub-
21
paragraph (A), an amount shall be treated as 
22
allocable to a qualified medical manufacturing 
23
facility only if such amount is with respect to 
24
employment of an individual for services pro-
25
19:02 Jul 28, 2020
H7527
6 
•HR 7527 IH
vided, and the principal place of employment of 
1
whom is, in such facility. 
2
‘‘(3) QUALIFIED MEDICAL MANUFACTURING FA-
3
CILITY.—The term ‘qualified medical manufacturing 
4
facility’ means any facility that— 
5
‘‘(A) researches and develops or produces 
6
medical products, and 
7
‘‘(B) is located within an economically dis-
8
tressed zone. 
9
‘‘(4) QUALIFIED MEDICAL MANUFACTURING FA-
10
CILITY
PROPERTY.—The term ‘qualified medical 
11
manufacturing facility property’ means any property 
12
used in (or consisting of) a qualified medical manu-
13
facturing facility if such property is directly con-
14
nected to the research, development, or production 
15
of a medical product. 
16
‘‘(5) MEDICAL PRODUCT.—The term ‘medical 
17
product’ means— 
18
‘‘(A) 
any 
prescription 
pharmaceutical 
19
which— 
20
‘‘(i) is subject to regulation under— 
21
‘‘(I) section 505 of the Federal 
22
Food, Drug, and Cosmetic Act (21 
23
U.S.C. 355), 
24
19:02 Jul 28, 2020
H7527
7 
•HR 7527 IH
‘‘(II) section 802 of such Act (21 
1
U.S.C. 382), or 
2
‘‘(III) section 351 of the Public 
3
Health Service Act (42 U.S.C. 262), 
4
or 
5
‘‘(ii) is described in section 201(jj) of 
6
the Federal Food, Drug, and Cosmetic Act 
7
(21 U.S.C. 321(jj)), or 
8
‘‘(B) any device (as that term is defined by 
9
section 201(h) of the Federal Food, Drug, and 
10
Cosmetic Act (21 U.S.C. 321(h))) or part 
11
thereof. 
12
‘‘(6) AGGREGATION RULES.— 
13
‘‘(A) IN GENERAL.—For purposes of this 
14
section, members of an affiliated group shall be 
15
treated as a single taxpayer. 
16
‘‘(B) AFFILIATED GROUP.—The term ‘af-
17
filiated group’ means an affiliated group (as de-
18
fined in section 1504(a), determined without re-
19
gard to section 1504(b)(3)) one or more mem-
20
bers of which are engaged in the active conduct 
21
of a trade or business within an economically 
22
distressed zone. 
23
20:40 Jul 31, 2020
H7527
8 
•HR 7527 IH
‘‘SEC. 1400AA–2. CREDIT FOR ECONOMICALLY DISTRESSED 
1
ZONE PRODUCTS AND SERVICES ACQUIRED 
2
BY DOMESTIC MEDICAL MANUFACTURERS. 
3
‘‘(a) ALLOWANCE OF CREDIT.—In the case of an eli-
4
gible medical manufacturer, there shall be allowed as a 
5
credit against the tax imposed by subtitle A for the taxable 
6
year an amount equal to the applicable percentage of the 
7
aggregate amounts paid or incurred by the taxpayer dur-
8
ing such taxable year for qualified economically distressed 
9
zone products or services. 
10
‘‘(b) APPLICABLE PERCENTAGE.—For purposes of 
11
this section, the term applicable percentage means— 
12
‘‘(1) 30 percent in the case of amounts paid or 
13
incurred to persons not described in paragraph (2) 
14
or (3), 
15
‘‘(2) 40 percent in the case of amounts paid or 
16
incurred to an unrelated minority business, and 
17
‘‘(3) 5 percent in the case of amounts paid or 
18
incurred to a related person. 
19
‘‘(c) ELIGIBLE
MEDICAL
MANUFACTURER.—For 
20
purposes of this section, the term ‘eligible medical manu-
21
facturer’ means any person in the trade or business of pro-
22
ducing medical products in the United States. 
23
‘‘(d) QUALIFIED PRODUCT OR SERVICE.—For pur-
24
poses of this section, the term ‘qualified product or service’ 
25
means— 
26
19:02 Jul 28, 2020
H7527
9 
•HR 7527 IH
‘‘(1) any product which is produced in an eco-
1
nomically distressed zone and which is integrated 
2
into a medical product produced by the taxpayer, 
3
and 
4
‘‘(2) any service which is provided in an eco-
5
nomically distressed zone and which is necessary to 
6
the production of a medical product by the taxpayer 
7
(including packaging). 
8
‘‘(e) MINORITY BUSINESS.—For purposes of this sec-
9
tion— 
10
‘‘(1) IN GENERAL.—The term ‘minority busi-
11
ness’ means— 
12
‘‘(A) a sole proprietorship carried on by a 
13
qualified individual, or 
14
‘‘(B) a corporation or partnership— 
15
‘‘(i) at least 50 percent of the owner-
16
ship interests in which are held by one or 
17
more qualified individuals, and 
18
‘‘(ii) of which a qualified individual is 
19
the president or chief executive officer (or 
20
a substantially equivalent position). 
21
‘‘(2) QUALIFIED INDIVIDUAL.—The term ‘quali-
22
fied individual’ means any individual who— 
23
19:02 Jul 28, 2020
H7527
10 
•HR 7527 IH
‘‘(A) is of Asian-Indian, Asian-Pacific, 
1
Black, Hispanic, or Native American origin or 
2
descent, and 
3
‘‘(B) is a United States citizen or legal 
4
resident of the United States or any of its terri-
5
tories or possessions. 
6
‘‘(f) RELATED PERSONS.—For purposes of this sec-
7
tion, persons shall be treated as related to each other if 
8
such persons would be treated as a single employer under 
9
the regulations prescribed under section 52(b). 
10
‘‘(g) OTHER TERMS.—Terms used in this section 
11
which are also used in section 1400AA–1 shall have the 
12
same meaning as when used in such section. 
13
‘‘SEC. 1400AA–3. SPECIAL RULES TO SECURE THE NATIONAL 
14
SUPPLY CHAIN AND FOR THE PRODUCTION 
15
OF POPULATION HEALTH PRODUCTS. 
16
‘‘(a) IN GENERAL.—In the case of a qualified repatri-
17
ated medical manufacturing facility or a qualified popu-
18
lation health product manufacturing facility— 
19
‘‘(1) section 1400AA–1(a) shall be applied by 
20
substituting ‘60 percent’ for ‘40 percent’, and 
21
‘‘(2) section 1400AA–2(a) shall be applied— 
22
‘‘(A) by substituting ‘50 percent’ for ‘30 
23
percent’, and 
24
19:02 Jul 28, 2020
H7527
11 
•HR 7527 IH
‘‘(B) by substituting ‘60 percent’ for ‘40 
1
percent’. 
2
‘‘(b) ELECTION TO EXPENSE IN LIEU OF TAX CRED-
3
IT FOR DEPRECIATION.—In the case of a taxpayer which 
4
elects (at such time and in such manner as the Secretary 
5
may provide) the application of this subsection with re-
6
spect to any qualified repatriated medical manufacturing 
7
facility or qualified population health product manufac-
8
turing facility— 
9
‘‘(1) section 1400AA–1(a)(3) shall not apply 
10
with respect to any qualified medical manufacturing 
11
facility property with respect to such facility, and 
12
‘‘(2) for purposes of section 168(k)— 
13
‘‘(A) such property shall be treated as 
14
qualified property, and 
15
‘‘(B) the applicable percentage with respect 
16
to such property shall be 100 percent. 
17
‘‘(c) QUALIFIED REPATRIATED MEDICAL MANUFAC-
18
TURING FACILITY.—For purposes of this section, the term 
19
‘qualified repatriated medical manufacturing facility’ 
20
means any qualified medical manufacturing facility (as de-
21
fined in section 1400AA–1) the production of which was 
22
moved to an economically distressed zone from a foreign 
23
country that the United States Trade Representative has 
24
19:02 Jul 28, 2020
H7527
12 
•HR 7527 IH
determined could pose a risk to the national supply chain 
1
because of political or social factors. 
2
‘‘(d) QUALIFIED POPULATION HEALTH PRODUCT 
3
MANUFACTURING FACILITY.—For purposes of this sec-
4
tion, the term ‘qualified population health product manu-
5
facturing facility’ means any qualified medical manufac-
6
turing facility (as defined in section 1400AA–1) that pro-
7
duces a population health product (as defined in section 
8
319L(a)(11) of the Public Health Service Act) which the 
9
Secretary of Health and Human Services has identified 
10
for support through a strategic initiative under section 
11
319L(c)(4)(F)(ii) of the Public Health Service Act. 
12
‘‘SEC. 1400AA–4. DESIGNATION OF ECONOMICALLY DIS-
13
TRESSED ZONES. 
14
‘‘(a) IN GENERAL.—For purposes of this subchapter, 
15
the term ‘economically distressed zone’ means any popu-
16
lation census tract within the United States which— 
17
‘‘(1) has a poverty rate of not less than 35 per-
18
cent for each of the 5 most recent calendar years for 
19
which information is available, or 
20
‘‘(2) satisfies each of the following require-
21
ments: 
22
‘‘(A) has pervasive poverty, unemployment, 
23
low labor force participation, and general dis-
24
tress measured as a prolonged period of eco-
25
19:02 Jul 28, 2020
H7527
13 
•HR 7527 IH
nomic decline measured by real gross national 
1
product, 
2
‘‘(B) has a poverty rate of not less than 30 
3
percent for each of the 5 most recent calendar 
4
years for which information is available, and 
5
‘‘(C) has been designated as such by the 
6
Secretary and the Secretary of Commerce pur-
7
suant to an application under subsection (b). 
8
‘‘(b) APPLICATION FOR DESIGNATION.— 
9
‘‘(1) IN GENERAL.—An application for designa-
10
tion as an economically distressed zone may be filed 
11
by a State or local government in which the popu-
12
lation census tract to which the application applies 
13
is located. 
14
‘‘(2) REQUIREMENTS.—Such application shall 
15
include a strategic plan for accomplishing the pur-
16
poses of this subchapter, which— 
17
‘‘(A) describes the coordinated economic, 
18
human, community, and physical development 
19
plan and related activities proposed for the 
20
nominated area, 
21
‘‘(B) describes the process by which the af-
22
fected community is a full partner in the proc-
23
ess of developing and implementing the plan 
24
and the extent to which local institutions and 
25
19:02 Jul 28, 2020
H7527
14 
•HR 7527 IH
organizations have contributed to the planning 
1
process, 
2
‘‘(C) identifies the amount of State, local, 
3
and private resources that will be available in 
4
the nominated area and the private/public part-
5
nerships to be used, which may include partici-
6
pation by, and cooperation with, universities, 
7
medical centers, and other private and public 
8
entities, 
9
‘‘(D) identifies the funding requested 
10
under any Federal program in support of the 
11
proposed economic, human, community, and 
12
physical development and related activities, 
13
‘‘(E) identifies baselines, methods, and 
14
benchmarks for measuring the success of car-
15
rying out the strategic plan, including the ex-
16
tent to which poor persons and families will be 
17
empowered to become economically self-suffi-
18
cient, and 
19
‘‘(F) does not include any action to assist 
20
any establishment in relocating from one area 
21
outside the nominated area to the nominated 
22
area, except that assistance for the expansion of 
23
an existing business entity through the estab-
24
19:02 Jul 28, 2020
H7527
15 
•HR 7527 IH
lishment of a new branch, affiliate, or sub-
1
sidiary is permitted if— 
2
‘‘(i) the establishment of the new 
3
branch, affiliate, or subsidiary will not re-
4
sult in a decrease in employment in the 
5
area of original location or in any other 
6
area where the existing business entity 
7
conducts business operations, 
8
‘‘(ii) there is no reason to believe that 
9
the new branch, affiliate, or subsidiary is 
10
being established with the intention of clos-
11
ing down the operations of the existing 
12
business entity in the area of its original 
13
location or in any other area where the ex-
14
isting business entity conducts business op-
15
eration, and 
16
‘‘(iii) includes such other information 
17
as may be required by the Secretary and 
18
the Secretary of Commerce. 
19
‘‘(c) PERIOD FOR WHICH DESIGNATIONS ARE IN EF-
20
FECT.—Designation as an economically distressed zone 
21
may be made at any time during the 10-year period begin-
22
ning on the date of the enactment of this section, and shall 
23
remain in effect with respect to such zone during the 15- 
24
year period beginning on the date of such designation. 
25
19:02 Jul 28, 2020
H7527
16 
•HR 7527 IH
Economically distressed zones described in subsection 
1
(a)(1) shall take effect on the date of the enactment of 
2
this Act and shall remain in effect during the 15-year pe-
3
riod beginning on such date. 
4
‘‘(d) TERRITORIES
AND POSSESSIONS.—The term 
5
‘United States’ includes the 50 States, the District of Co-
6
lumbia, and the territories and possessions of the United 
7
States. 
8
‘‘(e) REGULATIONS.—The Secretary shall issue such 
9
regulations or other guidance as may be necessary or ap-
10
propriate to carry out the purposes of this section, includ-
11
ing— 
12
‘‘(1) not later than 30 days after the date of 
13
the enactment of this section, a list of the population 
14
census tracts described in subsection (a)(1), and 
15
‘‘(2) not later than 60 days after the date of 
16
the enactment of this section, regulations or other 
17
guidance regarding the designation of population 
18
census tracts described in subsection (a)(2).’’. 
19
(b) EFFECTIVE DATE.—The amendments made by 
20
this section shall apply to taxable years beginning after 
21
December 31, 2019. 
22
SEC. 3. AUTHORITY TO SUPPORT DEVELOPMENT OF POPU-
23
LATION HEALTH PRODUCTS. 
24
(a) DEFINITIONS.— 
25
19:02 Jul 28, 2020
H7527
17 
•HR 7527 IH
(1) QUALIFIED
COUNTERMEASURE.—Subpara-
1
graph (A) of section 319F–1(a)(2) of the Public 
2
Health Service Act (42 U.S.C. 247d–6a(a)(2)) is 
3
amended to read as follows: 
4
‘‘(A) QUALIFIED COUNTERMEASURE.—The 
5
term ‘qualified countermeasure’ means a drug 
6
(as that term is defined by section 201(g)(1) of 
7
the Federal Food, Drug, and Cosmetic Act (21 
8
U.S.C. 321(g)(1))), biological product (as that 
9
term is defined by section 351(i) of this Act (42 
10
U.S.C. 262(i))), or device (as that term is de-
11
fined by section 201(h) of the Federal Food, 
12
Drug, and Cosmetic Act (21 U.S.C. 321(h))), 
13
that the Secretary determines to be a priority 
14
consistent with sections 302(2) and 304(a) of 
15
the Homeland Security Act of 2002— 
16
‘‘(i) to diagnose, mitigate, prevent, or 
17
treat harm from any biological agent (in-
18
cluding organisms that cause an infectious 
19
disease), toxin, chemical, radiological, or 
20
nuclear agent that may cause a public 
21
health emergency affecting national secu-
22
rity; or 
23
‘‘(ii) to diagnose, mitigate, prevent, or 
24
treat harm from an underlying non-com-
25
20:40 Jul 31, 2020
H7527
18 
•HR 7527 IH
municable disease which, combined with 
1
pandemic influenza or an emerging infec-
2
tious disease, may result in adverse health 
3
consequences or serious threat to one or 
4
more vulnerable American populations (as 
5
defined in section 319L(a)) in an epidemic 
6
or pandemic.’’. 
7
(2) OTHER
DEFINITIONS.—Subsection (a) of 
8
section 319L of the Public Health Service Act (42 
9
U.S.C. 247d–7e) is amended by adding at the end 
10
the following new paragraphs: 
11
‘‘(11) POPULATION
HEALTH
PRODUCT.—The 
12
term ‘population health product’ means a widely 
13
available drug to diagnose, mitigate, prevent, or 
14
treat harm from an underlying non-communicable 
15
disease which, combined with pandemic influenza or 
16
an emerging infectious disease, may result in ad-
17
verse health consequences or a serious threat to one 
18
or more vulnerable American populations in an epi-
19
demic or pandemic. 
20
‘‘(12) 
VULNERABLE
AMERICAN
21
LATIONS.—The term ‘vulnerable American popu-
22
lations’ means children, pregnant women, older 
23
adults, minority populations, and other at-risk indi-
24
viduals with relevant characteristics that warrant 
25
19:02 Jul 28, 2020
H7527
19 
•HR 7527 IH
consideration during the process of researching and 
1
developing such countermeasures and products.’’. 
2
(b) STRATEGIC INITIATIVES.—Clause (ii) of section 
3
319L(c)(4)(F) of the Public Health Service Act (42 
4
U.S.C. 247d–7e(c)(4)(F)) is amended to read as follows: 
5
‘‘(ii) threats that consistently exist or 
6
continually circulate and have a significant 
7
potential to become a pandemic, such as 
8
pandemic influenza and emerging infec-
9
tious diseases in combination with under-
10
lying non-communicable diseases, which 
11
may include the advanced research and de-
12
velopment, manufacturing, and appropriate 
13
stockpiling of qualified pandemic or epi-
14
demic products, and products, technologies, 
15
or processes to support the advanced re-
16
search and development of such counter-
17
measures (including multiuse platform 
18
technologies for diagnostics, vaccines, and 
19
therapeutics; virus seeds; clinical trial lots; 
20
novel virus strains; and antigen and adju-
21
vant material); and’’. 
22
(c) AT-RISK INDIVIDUALS.—Paragraph (6) of section 
23
319L(c) of the Public Health Service Act (42 U.S.C. 
24
247d–7e(c)) is amended to read as follows: 
25
19:02 Jul 28, 2020
H7527
20 
•HR 7527 IH
‘‘(6) AT-RISK
INDIVIDUALS.—In carrying out 
1
the functions under this section, the Secretary may 
2
give a priority to advanced research and develop-
3
ment of— 
4
‘‘(A) qualified countermeasures and quali-
5
fied pandemic or epidemic products likely to be 
6
safe and effective with respect to vulnerable 
7
American populations; and 
8
‘‘(B) population health products likely to 
9
protect vulnerable American populations with 
10
underlying non-communicable diseases from dis-
11
proportionate 
harm 
in 
epidemics 
and 
12
pandemics.’’. 
13
(d) OTHER AUTHORITIES.—Section 319L(c) of the 
14
Public Health Service Act (42 U.S.C. 247d–7e(c)) is 
15
amended by adding at the end the following: 
16
‘‘(8) 
TIMELY
DELIVERY
OF
17
HEALTH PRODUCTS TO AT-RISK INDIVIDUALS.—The 
18
Secretary shall collaborate with the Administrator of 
19
the Centers for Medicare & Medicaid Services, the 
20
Secretary of Defense, the Secretary of Veterans Af-
21
fairs, the Commissioner of Food and Drugs, and the 
22
heads of other Federal agencies involved with ap-
23
proval and distribution of health products to assure 
24
that such Federal agencies distribute approved pop-
25
19:02 Jul 28, 2020
H7527
21 
•HR 7527 IH
ulation health products as promptly and effectively 
1
as possible, and as continuously as possible, to pro-
2
tect vulnerable American populations from harm in 
3
epidemics and pandemics. 
4
‘‘(9) REPORT ON NEED FOR INCENTIVIZING DE-
5
VELOPMENT OF POPULATION HEALTH PRODUCTS.— 
6
Not later than 90 days after the date of enactment 
7
of the Medical Manufacturing, Economic Develop-
8
ment, and Sustainability Act of 2020, the Secretary 
9
shall examine and report to the Congress on— 
10
‘‘(A) the extent to which the health of 
11
aging Americans, African Americans, His-
12
panics, Native Americans, veterans, or other 
13
vulnerable American populations has been dis-
14
proportionately harmed by the COVID–19 pan-
15
demic and prior epidemics and pandemics; 
16
‘‘(B) the population health products cur-
17
rently available and whether there is a need for 
18
additional 
innovation 
and 
development 
to 
19
produce population health products to reduce 
20
the exposure of vulnerable American popu-
21
lations to risk of disproportionate harm in 
22
epidemics and pandemics; and 
23
‘‘(C) whether the Secretary recommends 
24
providing the same incentives for the develop-
25
19:02 Jul 28, 2020
H7527
22 
•HR 7527 IH
ment and marketing of population health prod-
1
ucts as is given with respect to covered infec-
2
tious disease products under the Federal Food, 
3
Drug, and Cosmetic Act, including under sec-
4
tion 505E of such Act.’’. 
5
Æ 
19:02 Jul 28, 2020
H7527
